[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 13, Issue 4 (Autumn 2022) ::
Caspian J Intern Med 2022, 13(4): 728-734 Back to browse issues page
Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin
Hossein Ghalehnoei , Ahmad Hormati , Amir Houshang Mohammad Alizadeh , Sajjad Ahmadpour , Seyed Hassan Abedi *
Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol Iran , h.abedi@mubabol.ac.ir
Abstract:   (267 Views)
Background: Pancreatitis is one of the most crucial complications following endoscopic retrograde cholangiopancreatography (ERCP). The purpose of the current study was to investigate patient-related post-ERCP pancreatitis (PEP) risk factors in two groups of patients: prophylactic pancreatic stent and rectal indomethacin.
Methods: Two different prophylactic modalities were planned and complications were assessed based on the defined inclusion criteria. In this study, the patients were evaluated for the procedure and patient-related risk factors in post-ERCP pancreatitis in the recipient groups of the prophylactic pancreatic stent and rectal indomethacin.
Results: Pancreatitis was confirmed in 27 of all 170 selected patients after ERCP. By univariate analysis, two variables were significant with the development of PEP. Regarding the patient-related risk factors, unique subjects with common bile duct (CBD) dilated 10mm were more exposed to an increased chance of PEP (P=0. 015); meanwhile, other factors did not correlate with the increased possibility of PEP in both groups. The only procedure-related risk factor for PEP was the deep cannulation of the pancreatic duct in both groups during the procedure with an incremental significant incidence of pancreatitis (P=0.005). Comparison of prophylactic pancreatic stent and rectal indomethacin showed no effects in term of post ERCP pancreatitis reduction. Additionally, there was no significant difference between these two strategies in the rate of PEP.
Conclusion: Prophylactic pancreatic duct stents and administration of rectal indomethacin cannot have particular approaches for reducing the possible occurrence of PEP. The increase in time of deep cannulation and the presence of CBD dilation <10mm could be considered as important risk factors.

 
Keywords: ERCP, post ERCP pancreatitis, pancreatic duct stent, rectal indomethacin
Full-Text [PDF 196 kb]   (210 Downloads)    
Type of Study: Original Article | Subject: Gastroentrology
Received: 2021/08/1 | Accepted: 2022/01/26 | Published: 2022/09/28
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghalehnoei H, Hormati A, Mohammad Alizadeh A H, Ahmadpour S, Abedi S H. Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin. Caspian J Intern Med 2022; 13 (4) :728-734
URL: http://caspjim.com/article-1-3033-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 4 (Autumn 2022) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4508